Which has stronger valuation & earnings, LXEO or BCAX?

Bicara Therapeutics is trading at a lower price-to-earnings ratio than Lexeo Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Lexeo Therapeutics N/A N/A -$99.96M -$1.15 N/A Bicara Therapeutics N/A N/A -$137.95M -$3.10 N/A

Is LXEO or BCAX more profitable?

Bicara Therapeutics' return on equity of -41.49% beat Lexeo Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Lexeo Therapeutics N/A -41.85% -38.03% Bicara Therapeutics N/A -41.49% -38.59%

Does the media refer more to LXEO or BCAX?

In the previous week, Bicara Therapeutics had 2 more articles in the media than Lexeo Therapeutics. MarketBeat recorded 8 mentions for Bicara Therapeutics and 6 mentions for Lexeo Therapeutics. Lexeo Therapeutics' average media sentiment score of 1.77 beat Bicara Therapeutics' score of 1.21 indicating that Lexeo Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lexeo Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Bicara Therapeutics 5 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is ABSI or LXEO more profitable?

Lexeo Therapeutics has a net margin of 0.00% compared to Absci's net margin of -7,756.38%. Lexeo Therapeutics' return on equity of -41.85% beat Absci's return on equity. Company Net Margins Return on Equity Return on Assets Absci -7,756.38% -61.71% -54.52% Lexeo Therapeutics N/A -41.85% -38.03%

Does the media favor ABSI or LXEO?

In the previous week, Absci had 2 more articles in the media than Lexeo Therapeutics. MarketBeat recorded 8 mentions for Absci and 6 mentions for Lexeo Therapeutics. Lexeo Therapeutics' average media sentiment score of 1.77 beat Absci's score of 1.26 indicating that Lexeo Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Absci 5 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Lexeo Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has higher valuation and earnings, FBRX or LXEO?

Forte Biosciences is trading at a lower price-to-earnings ratio than Lexeo Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Forte Biosciences N/A N/A -$69.38M -$4.65 N/A Lexeo Therapeutics N/A N/A -$99.96M -$1.15 N/A

Is FBRX or LXEO more profitable?

Lexeo Therapeutics' return on equity of -41.85% beat Forte Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Forte Biosciences N/A -94.82% -77.68% Lexeo Therapeutics N/A -41.85% -38.03%

Does the media prefer FBRX or LXEO?

In the previous week, Forte Biosciences had 2 more articles in the media than Lexeo Therapeutics. MarketBeat recorded 8 mentions for Forte Biosciences and 6 mentions for Lexeo Therapeutics. Lexeo Therapeutics' average media sentiment score of 1.77 beat Forte Biosciences' score of 0.80 indicating that Lexeo Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Forte Biosciences 2 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Lexeo Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has preferable earnings and valuation, TRAX or LXEO?

First Tracks Biotherapeutics is trading at a lower price-to-earnings ratio than Lexeo Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio First Tracks Biotherapeutics N/A N/A N/A -$1.84 N/A Lexeo Therapeutics N/A N/A -$99.96M -$1.15 N/A

Is TRAX or LXEO more profitable?

First Tracks Biotherapeutics' return on equity of 0.00% beat Lexeo Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets First Tracks Biotherapeutics N/A N/A N/A Lexeo Therapeutics N/A -41.85% -38.03%

Does the media refer more to TRAX or LXEO?

In the previous week, Lexeo Therapeutics had 3 more articles in the media than First Tracks Biotherapeutics. MarketBeat recorded 6 mentions for Lexeo Therapeutics and 3 mentions for First Tracks Biotherapeutics. Lexeo Therapeutics' average media sentiment score of 1.77 beat First Tracks Biotherapeutics' score of 0.94 indicating that Lexeo Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment First Tracks Biotherapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Lexeo Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has preferable valuation and earnings, LXEO or AAPG?

Lexeo Therapeutics has higher earnings, but lower revenue than Ascentage Pharma Group International. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Lexeo Therapeutics N/A N/A -$99.96M -$1.15 N/A Ascentage Pharma Group International $642.64M 2.66 -$177.71M N/A N/A

Is LXEO or AAPG more profitable?

Ascentage Pharma Group International's return on equity of 0.00% beat Lexeo Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Lexeo Therapeutics N/A -41.85% -38.03% Ascentage Pharma Group International N/A N/A N/A

Does the media refer more to LXEO or AAPG?

In the previous week, Lexeo Therapeutics had 1 more articles in the media than Ascentage Pharma Group International. MarketBeat recorded 6 mentions for Lexeo Therapeutics and 5 mentions for Ascentage Pharma Group International. Lexeo Therapeutics' average media sentiment score of 1.77 beat Ascentage Pharma Group International's score of 0.78 indicating that Lexeo Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lexeo Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Ascentage Pharma Group International 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Lexeo Therapeutics (LXEO) Competitors

$4.86 -0.13 (-2.61%)

As of 08/28/2026 04:00 PM Eastern

Compare

LXEO vs. BCAX, ABSI, FBRX, TRAX, and AAPG

Should you buy Lexeo Therapeutics stock or one of its competitors? Lexeo Therapeutics's main competitors and comparable companies include Bicara Therapeutics (BCAX), Absci (ABSI), Forte Biosciences (FBRX), First Tracks Biotherapeutics (TRAX), and Ascentage Pharma Group International (AAPG). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Lexeo Therapeutics compare to Bicara Therapeutics?

Lexeo Therapeutics (NASDAQ:LXEO) and Bicara Therapeutics (NASDAQ:BCAX) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, profitability, media sentiment, institutional ownership, dividends, valuation and risk.

Bicara Therapeutics' return on equity of -41.49% beat Lexeo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lexeo Therapeutics	N/A	-41.85%	-38.03%
Bicara Therapeutics	N/A	-41.49%	-38.59%

In the previous week, Bicara Therapeutics had 2 more articles in the media than Lexeo Therapeutics. MarketBeat recorded 8 mentions for Bicara Therapeutics and 6 mentions for Lexeo Therapeutics. Lexeo Therapeutics' average media sentiment score of 1.77 beat Bicara Therapeutics' score of 1.21 indicating that Lexeo Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lexeo Therapeutics	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Bicara Therapeutics	5 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

60.7% of Lexeo Therapeutics shares are owned by institutional investors. 2.0% of Lexeo Therapeutics shares are owned by insiders. Comparatively, 13.8% of Bicara Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Lexeo Therapeutics has a beta of 1.46, indicating that its stock price is 46% more volatile than the broader market. Comparatively, Bicara Therapeutics has a beta of -0.75, indicating that its stock price is 175% less volatile than the broader market.

Lexeo Therapeutics currently has a consensus target price of $18.75, indicating a potential upside of 285.80%. Bicara Therapeutics has a consensus target price of $32.64, indicating a potential upside of 39.29%. Given Lexeo Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Lexeo Therapeutics is more favorable than Bicara Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lexeo Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	3.00
Bicara Therapeutics	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.80

Bicara Therapeutics is trading at a lower price-to-earnings ratio than Lexeo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lexeo Therapeutics	N/A	N/A	-$99.96M	-$1.15	N/A
Bicara Therapeutics	N/A	N/A	-$137.95M	-$3.10	N/A

Summary

Lexeo Therapeutics beats Bicara Therapeutics on 9 of the 13 factors compared between the two stocks.

How does Lexeo Therapeutics compare to Absci?

Absci (NASDAQ:ABSI) and Lexeo Therapeutics (NASDAQ:LXEO) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, risk, earnings, dividends, valuation, analyst recommendations, institutional ownership and media sentiment.

52.1% of Absci shares are held by institutional investors. Comparatively, 60.7% of Lexeo Therapeutics shares are held by institutional investors. 10.5% of Absci shares are held by company insiders. Comparatively, 2.0% of Lexeo Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Absci presently has a consensus target price of $13.43, indicating a potential upside of 54.17%. Lexeo Therapeutics has a consensus target price of $18.75, indicating a potential upside of 285.80%. Given Lexeo Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Lexeo Therapeutics is more favorable than Absci.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Absci	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.78
Lexeo Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	3.00

In the previous week, Absci had 2 more articles in the media than Lexeo Therapeutics. MarketBeat recorded 8 mentions for Absci and 6 mentions for Lexeo Therapeutics. Lexeo Therapeutics' average media sentiment score of 1.77 beat Absci's score of 1.26 indicating that Lexeo Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Absci	5 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lexeo Therapeutics	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Lexeo Therapeutics has a net margin of 0.00% compared to Absci's net margin of -7,756.38%. Lexeo Therapeutics' return on equity of -41.85% beat Absci's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Absci	-7,756.38%	-61.71%	-54.52%
Lexeo Therapeutics	N/A	-41.85%	-38.03%

Absci has a beta of 2.35, meaning that its stock price is 135% more volatile than the broader market. Comparatively, Lexeo Therapeutics has a beta of 1.46, meaning that its stock price is 46% more volatile than the broader market.

Lexeo Therapeutics has lower revenue, but higher earnings than Absci. Absci is trading at a lower price-to-earnings ratio than Lexeo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Absci	$2.80M	533.83	-$115.18M	-$0.80	N/A
Lexeo Therapeutics	N/A	N/A	-$99.96M	-$1.15	N/A

Summary

Lexeo Therapeutics beats Absci on 10 of the 16 factors compared between the two stocks.

How does Lexeo Therapeutics compare to Forte Biosciences?

Forte Biosciences (NASDAQ:FBRX) and Lexeo Therapeutics (NASDAQ:LXEO) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, profitability, dividends, media sentiment, risk, analyst recommendations, earnings and institutional ownership.

In the previous week, Forte Biosciences had 2 more articles in the media than Lexeo Therapeutics. MarketBeat recorded 8 mentions for Forte Biosciences and 6 mentions for Lexeo Therapeutics. Lexeo Therapeutics' average media sentiment score of 1.77 beat Forte Biosciences' score of 0.80 indicating that Lexeo Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Forte Biosciences	2 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lexeo Therapeutics	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

77.6% of Forte Biosciences shares are held by institutional investors. Comparatively, 60.7% of Lexeo Therapeutics shares are held by institutional investors. 4.4% of Forte Biosciences shares are held by insiders. Comparatively, 2.0% of Lexeo Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Forte Biosciences has a beta of 2.62, indicating that its stock price is 162% more volatile than the broader market. Comparatively, Lexeo Therapeutics has a beta of 1.46, indicating that its stock price is 46% more volatile than the broader market.

Lexeo Therapeutics' return on equity of -41.85% beat Forte Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Forte Biosciences	N/A	-94.82%	-77.68%
Lexeo Therapeutics	N/A	-41.85%	-38.03%

Forte Biosciences is trading at a lower price-to-earnings ratio than Lexeo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Forte Biosciences	N/A	N/A	-$69.38M	-$4.65	N/A
Lexeo Therapeutics	N/A	N/A	-$99.96M	-$1.15	N/A

Forte Biosciences presently has a consensus price target of $71.67, suggesting a potential downside of 6.91%. Lexeo Therapeutics has a consensus price target of $18.75, suggesting a potential upside of 285.80%. Given Lexeo Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Lexeo Therapeutics is more favorable than Forte Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Forte Biosciences	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Lexeo Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	3.00

Summary

Lexeo Therapeutics beats Forte Biosciences on 9 of the 14 factors compared between the two stocks.

How does Lexeo Therapeutics compare to First Tracks Biotherapeutics?

First Tracks Biotherapeutics (NASDAQ:TRAX) and Lexeo Therapeutics (NASDAQ:LXEO) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, risk, profitability, dividends, earnings and media sentiment.

First Tracks Biotherapeutics presently has a consensus target price of $63.00, indicating a potential upside of 50.50%. Lexeo Therapeutics has a consensus target price of $18.75, indicating a potential upside of 285.80%. Given Lexeo Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Lexeo Therapeutics is more favorable than First Tracks Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
First Tracks Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73
Lexeo Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	3.00

60.7% of Lexeo Therapeutics shares are owned by institutional investors. 2.0% of Lexeo Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Lexeo Therapeutics had 3 more articles in the media than First Tracks Biotherapeutics. MarketBeat recorded 6 mentions for Lexeo Therapeutics and 3 mentions for First Tracks Biotherapeutics. Lexeo Therapeutics' average media sentiment score of 1.77 beat First Tracks Biotherapeutics' score of 0.94 indicating that Lexeo Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
First Tracks Biotherapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lexeo Therapeutics	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

First Tracks Biotherapeutics' return on equity of 0.00% beat Lexeo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
First Tracks Biotherapeutics	N/A	N/A	N/A
Lexeo Therapeutics	N/A	-41.85%	-38.03%

First Tracks Biotherapeutics is trading at a lower price-to-earnings ratio than Lexeo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
First Tracks Biotherapeutics	N/A	N/A	N/A	-$1.84	N/A
Lexeo Therapeutics	N/A	N/A	-$99.96M	-$1.15	N/A

Summary

Lexeo Therapeutics beats First Tracks Biotherapeutics on 9 of the 12 factors compared between the two stocks.

How does Lexeo Therapeutics compare to Ascentage Pharma Group International?

Lexeo Therapeutics (NASDAQ:LXEO) and Ascentage Pharma Group International (NASDAQ:AAPG) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, media sentiment, profitability, analyst recommendations, institutional ownership, earnings, dividends and risk.

In the previous week, Lexeo Therapeutics had 1 more articles in the media than Ascentage Pharma Group International. MarketBeat recorded 6 mentions for Lexeo Therapeutics and 5 mentions for Ascentage Pharma Group International. Lexeo Therapeutics' average media sentiment score of 1.77 beat Ascentage Pharma Group International's score of 0.78 indicating that Lexeo Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lexeo Therapeutics	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Ascentage Pharma Group International	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Ascentage Pharma Group International's return on equity of 0.00% beat Lexeo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lexeo Therapeutics	N/A	-41.85%	-38.03%
Ascentage Pharma Group International	N/A	N/A	N/A

Lexeo Therapeutics has higher earnings, but lower revenue than Ascentage Pharma Group International.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lexeo Therapeutics	N/A	N/A	-$99.96M	-$1.15	N/A
Ascentage Pharma Group International	$642.64M	2.66	-$177.71M	N/A	N/A

Lexeo Therapeutics has a beta of 1.46, indicating that its share price is 46% more volatile than the broader market. Comparatively, Ascentage Pharma Group International has a beta of 0.1, indicating that its share price is 90% less volatile than the broader market.

Lexeo Therapeutics currently has a consensus target price of $18.75, suggesting a potential upside of 285.80%. Ascentage Pharma Group International has a consensus target price of $46.43, suggesting a potential upside of 153.99%. Given Lexeo Therapeutics' higher probable upside, research analysts plainly believe Lexeo Therapeutics is more favorable than Ascentage Pharma Group International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lexeo Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	3.00
Ascentage Pharma Group International	0 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.20

60.7% of Lexeo Therapeutics shares are held by institutional investors. 2.0% of Lexeo Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Lexeo Therapeutics beats Ascentage Pharma Group International on 7 of the 12 factors compared between the two stocks.

Get Lexeo Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LXEO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LXEO vs. The Competition

Export

Metric	Lexeo Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$398.74M	$3.93B	$7.20B	$12.90B
Dividend Yield	N/A	3.61%	2.54%	11.28%
P/E Ratio	-4.23	11.62	273.16	25.45
Price / Sales	N/A	1,295.87	605.06	76.64
Price / Cash	N/A	106.39	76.74	53.00
Price / Book	1.69	16.53	12.98	6.14
Net Income	-$99.96M	-$22.80M	$3.48B	$348.86M
7 Day Performance	-0.41%	-0.31%	0.13%	-0.80%
1 Month Performance	11.72%	9.80%	7.08%	4.13%
1 Year Performance	1.46%	55.66%	24.67%	15.17%

Lexeo Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LXEO Lexeo Therapeutics	2.6933 of 5 stars	$4.86 -2.6%	$18.75 +285.8%	+1.5%	$398.74M	N/A	N/A	58	News Coverage Positive News
BCAX Bicara Therapeutics	2.3885 of 5 stars	$24.86 +5.4%	$32.64 +31.3%	+96.2%	$1.64B	N/A	N/A	32
ABSI Absci	2.8783 of 5 stars	$9.53 +7.8%	$13.43 +40.9%	+264.4%	$1.64B	$1.56M	N/A	210	Positive News Gap Down
FBRX Forte Biosciences	1.3905 of 5 stars	$76.96 +0.0%	$71.67 -6.9%	N/A	$1.63B	N/A	N/A	5	News Coverage Analyst Upgrade
TRAX First Tracks Biotherapeutics	3.3506 of 5 stars	$45.39 +4.9%	$63.00 +38.8%	N/A	$1.63B	N/A	N/A	N/A

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LXEO) was last updated on 8/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Lexeo Therapeutics (LXEO) Competitors

LXEO vs. BCAX, ABSI, FBRX, TRAX, and AAPG

How does Lexeo Therapeutics compare to Bicara Therapeutics?

Summary

How does Lexeo Therapeutics compare to Absci?

Summary

How does Lexeo Therapeutics compare to Forte Biosciences?

Summary

How does Lexeo Therapeutics compare to First Tracks Biotherapeutics?

Summary

How does Lexeo Therapeutics compare to Ascentage Pharma Group International?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LXEO vs. The Competition

Lexeo Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Lexeo Therapeutics (LXEO) Competitors

LXEO vs. BCAX, ABSI, FBRX, TRAX, and AAPG

How does Lexeo Therapeutics compare to Bicara Therapeutics?

Is LXEO or BCAX more profitable?

Does the media refer more to LXEO or BCAX?

Do insiders & institutionals believe in LXEO or BCAX?

Which has more volatility and risk, LXEO or BCAX?

Do analysts prefer LXEO or BCAX?

Which has stronger valuation & earnings, LXEO or BCAX?

Summary

How does Lexeo Therapeutics compare to Absci?

Do insiders & institutionals hold more shares of ABSI or LXEO?

Do analysts prefer ABSI or LXEO?

Does the media favor ABSI or LXEO?

Is ABSI or LXEO more profitable?

Which has more risk and volatility, ABSI or LXEO?

Which has stronger valuation and earnings, ABSI or LXEO?

Summary

How does Lexeo Therapeutics compare to Forte Biosciences?

Does the media prefer FBRX or LXEO?

Do institutionals & insiders hold more shares of FBRX or LXEO?

Which has more volatility and risk, FBRX or LXEO?

Is FBRX or LXEO more profitable?

Which has higher valuation and earnings, FBRX or LXEO?

Do analysts recommend FBRX or LXEO?

Summary

How does Lexeo Therapeutics compare to First Tracks Biotherapeutics?

Do analysts recommend TRAX or LXEO?

Do institutionals and insiders have more ownership in TRAX or LXEO?

Does the media refer more to TRAX or LXEO?

Is TRAX or LXEO more profitable?

Which has preferable earnings and valuation, TRAX or LXEO?

Summary

How does Lexeo Therapeutics compare to Ascentage Pharma Group International?

Does the media refer more to LXEO or AAPG?

Is LXEO or AAPG more profitable?

Which has preferable valuation and earnings, LXEO or AAPG?

Which has more volatility & risk, LXEO or AAPG?

Do analysts rate LXEO or AAPG?

Do insiders & institutionals have more ownership in LXEO or AAPG?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LXEO vs. The Competition

Lexeo Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools